Target intelligence / Profile preview

LIM and cysteine-rich domains protein 1 (LMCD1)

Target
LMCD1
Molecular classification
Transcription cofactor, LIM domain zinc finger protein, Other (multifunctional protein regulator)
01

Overview

LIM and cysteine-rich domains protein 1 (LMCD1) is a multifunctional transcriptional cofactor belonging to the LIM-domain family of zinc finger proteins, featuring an N-terminal cysteine-rich domain and two C-terminal LIM domains[1][3]. LMCD1 acts primarily as a transcriptional corepressor and modulator, notably interacting with and repressing GATA6 and other GATA family transcription factors by inhibiting their DNA binding, thereby restricting tissue-specific gene activation in the heart and lungs[1][2][3]. LMCD1 regulates multiple biological processes including cardiac hypertrophy (through calcineurin/NFAT signaling), skeletal muscle growth, vascular smooth muscle proliferation, osteogenic differentiation (by stabilizing key osteogenic regulators such as RUNX2 and Smad1), as well as cancer cell migration and epithelial-to-mesenchymal transition[3][4]. Disease associations include a role in cardiomyopathy, vascular disorders, osteoporosis, and the progression of several cancers[1][3][4].

Other names
LMCD1DyxinLIM and cysteine-rich domains 1Lim domain proteinLIM and cysteine-rich domains protein 1dyxin
02

Biological functions

Transcriptional corepression (notably of GATA6 and other GATA factors)Regulation of tissue-specific gene expression in lung and cardiac cellsModulation of calcineurin/nuclear factor of activated T-cells (NFAT) signaling in heart and muscleRegulation of osteogenic differentiation (osteogenesis)Regulation of cell proliferation and migration (especially in cancer and vascular smooth muscle)Positive regulation of skeletal muscle hypertrophyRegulation of protein stability (protection from ubiquitin-mediated degradation)
03

Disease associations

Cancer (notably hepatocellular carcinoma; promotes cell migration and metastasis)Cardiovascular disease (cardiac hypertrophy, vascular lesion development)Bone metabolism disorders (via osteogenic differentiation)Mixed cell uveal melanomaLidocaine allergy
04

Safety considerations

Overexpression or mutation may promote cancer cell migration and metastasis[3][4]Involvement in cardiac hypertrophy pathways may limit safe modulation in cardiovascular contexts[3]
05

Biomarkers

Potential biomarker for osteogenic differentiation in bone marrow stem cells[4]Marker for poor prognosis/metastatic potential in some cancers[3][4]

Beyond the preview

Go deeper on LIM and cysteine-rich domains protein 1 (LMCD1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LIM and cysteine-rich domains protein 1 (LMCD1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call